|
271 Companies |
|
374 Products |
|
374 Products |
|
160 Mechanisms of Action |
|
34 Trials |
|
5514 News |
|
| «12...56789101112131415...110111» |
- pegylated liposomal doxorubicin / Generic mfg., carboplatin / Generic mfg.
Enrollment change, Trial withdrawal: Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer (clinicaltrials.gov) - Nov 20, 2017
P1/2, N=0, Withdrawn, Sponsor: University of Texas Southwestern Medical Center
N=61 --> 0 | Completed --> Withdrawn
- | cisplatin / Generic mfg.
Trial completion, Surgery, Metastases: Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva (clinicaltrials.gov) - Nov 19, 2017
P2, N=61, Completed, Sponsor: Gynecologic Oncology Group
N=61 --> 0 | Completed --> Withdrawn Active, not recruiting --> Completed
- | Enrollment closed: Trans-perineal Trigger Point Dry Needling for Chronic Pelvic Pain (clinicaltrials.gov) - Nov 14, 2017
P=N/A, N=72, Active, not recruiting, Sponsor: Cork University Hospital
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Trial primary completion date: Outcomes of Uterine Rupture (clinicaltrials.gov) - Nov 14, 2017
P=N/A, N=100, Recruiting, Sponsor: Assiut University
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2017 --> Dec 2017
- | metformin / Generic mfg.
Preclinical, Trial initiation date, Trial primary completion date: Impact of Metformin on In Vitro Fertilization Outcomes in Overweight and Obese PCOS Women (clinicaltrials.gov) - Nov 14, 2017
P=N/A, N=102, Completed, Sponsor: Assiut University
Trial primary completion date: Aug 2017 --> Dec 2017 Initiation date: Jan 2014 --> Jan 2015 | Trial primary completion date: Dec 2014 --> Dec 2016
- | metformin / Generic mfg., carboplatin / Generic mfg., paclitaxel / Generic mfg.
Trial primary completion date, Combination therapy, Metastases: OVMET: Study of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer (clinicaltrials.gov) - Nov 13, 2017
P1, N=20, Recruiting, Sponsor: University Medical Center Groningen
Initiation date: Jan 2014 --> Jan 2015 | Trial primary completion date: Dec 2014 --> Dec 2016 Trial primary completion date: Jun 2017 --> Mar 2019
- | Trial completion, Trial primary completion date: Using CHWs or Mailing Self Sampling Home Tests to Increase Cervical Cancer Screening in South Florida (clinicaltrials.gov) - Nov 13, 2017
P=N/A, N=602, Completed, Sponsor: University of Miami
Trial primary completion date: Jun 2017 --> Mar 2019 Recruiting --> Completed | Trial primary completion date: Dec 2017 --> Aug 2017
- | Trial completion: Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors (clinicaltrials.gov) - Nov 9, 2017
P2, N=20, Completed, Sponsor: Children's Oncology Group
Recruiting --> Completed | Trial primary completion date: Dec 2017 --> Aug 2017 Active, not recruiting --> Completed
- | Trial completion, Enrollment change, Trial primary completion date: Hysteroscopic Assessment of Fallopian Tubal Patency (clinicaltrials.gov) - Nov 9, 2017
P=N/A, N=621, Completed, Sponsor: University of Mississippi Medical Center
Active, not recruiting --> Completed Recruiting --> Completed | N=1000 --> 621 | Trial primary completion date: Nov 2018 --> Oct 2017
- | Enrollment closed, Enrollment change, Trial primary completion date, MRI: Preoperative Staging of Endometriosis With MRI (clinicaltrials.gov) - Nov 8, 2017
P=N/A, N=120, Active, not recruiting, Sponsor: Universitaire Ziekenhuizen Leuven
Recruiting --> Completed | N=1000 --> 621 | Trial primary completion date: Nov 2018 --> Oct 2017 Recruiting --> Active, not recruiting | N=70 --> 120 | Trial primary completion date: Dec 2015 --> Sep 2016
- | Enrollment closed, Enrollment change: PCS: Preventing Congenital Syphilis (clinicaltrials.gov) - Nov 7, 2017
P=N/A, N=60386, Active, not recruiting, Sponsor: Tulane University School of Public Health and Tropical Medicine
Recruiting --> Active, not recruiting | N=70 --> 120 | Trial primary completion date: Dec 2015 --> Sep 2016 Recruiting --> Active, not recruiting | N=6000 --> 60386
- | Enrollment closed, Trial primary completion date: Clinical Tests to Predict the Success of Assisted Reproductive Techniques (clinicaltrials.gov) - Nov 7, 2017
P=N/A, N=542, Active, not recruiting, Sponsor: Martin Blomberg Jensen
Recruiting --> Active, not recruiting | N=6000 --> 60386 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2017 --> Dec 2017
- | Odomzo (sonidegib) / Sun Pharma
Trial completion, Trial primary completion date: Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer (clinicaltrials.gov) - Nov 6, 2017
P1, N=15, Completed, Sponsor: University of Alabama at Birmingham
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2017 --> Dec 2017 Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Dec 2016
- | Trial primary completion date: Multicomponent Intervention to Reduce Sexual Risk and Substance Use (clinicaltrials.gov) - Nov 6, 2017
P=N/A, N=240, Active, not recruiting, Sponsor: Hunter College of City University of New York
Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Dec 2016 Trial primary completion date: Jan 2017 --> Jan 2018
- | Trial completion, Enrollment change: Intestinal Microbiota Survey of Polycystic Ovary Syndrome (clinicaltrials.gov) - Nov 6, 2017
P=N/A, N=80, Completed, Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Trial primary completion date: Jan 2017 --> Jan 2018 Recruiting --> Completed | N=100 --> 80
- ||| TroVax (MVA 5T4) / Oxford Biomedica
Enrollment change, Trial primary completion date: TRIOC: The Activity of TroVax (clinicaltrials.gov) - Nov 1, 2017
P2, N=97, Recruiting, Sponsor: University College, London
Recruiting --> Completed | N=100 --> 80 N=75 --> 97 | Trial primary completion date: May 2017 --> May 2019
- | Enrollment closed, Head-to-Head: SALPINGOVA: Effect of Salpingectomy During Conservative Hysterectomy (clinicaltrials.gov) - Oct 31, 2017
P=N/A, N=350, Active, not recruiting, Sponsor: University Hospital, Tours
N=75 --> 97 | Trial primary completion date: May 2017 --> May 2019 Recruiting --> Active, not recruiting
- | Preclinical, Trial primary completion date: Clinical Effectiveness of Frozen Thawed Embryo Transfer Compared to Fresh Embryo Transfer (clinicaltrials.gov) - Oct 31, 2017
P=N/A, N=800, Recruiting, Sponsor: The University of Hong Kong
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2017 --> Dec 2019
- Recentin (cediranib) / AstraZeneca, Lynparza (olaparib) / Merck (MSD), AstraZeneca
Enrollment closed, Trial primary completion date, PARP Biomarker: A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib (clinicaltrials.gov) - Oct 31, 2017
P2, N=4, Active, not recruiting, Sponsor: University Health Network, Toronto
Trial primary completion date: Dec 2017 --> Dec 2019 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Jun 2018
- | Visanne (dienogest) / Mochida, Bayer
Enrollment change, Trial initiation date, Trial withdrawal, Surgery: DOROSY: Trial Comparing Preoperative Dienogest Therapy Followed by Surgery vs. Upfront Surgery to Save Ovarian Reserve in Young Women With Ovarian Endometrioma (clinicaltrials.gov) - Oct 31, 2017
P2, N=0, Withdrawn, Sponsor: Seoul National University Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Jun 2018 N=72 --> 0 | Initiation date: Apr 2016 --> Oct 2017 | Not yet recruiting --> Withdrawn
- | Vagifem (estradiol) / Novo Nordisk
Trial completion: The Vaginal Health Trial (clinicaltrials.gov) - Oct 30, 2017
P4, N=302, Completed, Sponsor: Fred Hutchinson Cancer Research Center
N=72 --> 0 | Initiation date: Apr 2016 --> Oct 2017 | Not yet recruiting --> Withdrawn Active, not recruiting --> Completed
- RG7882 / Roche
Enrollment change, Trial primary completion date: A Study Evaluating the Safety and Pharmacokinetics of DMUC4064A in Participants With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer (clinicaltrials.gov) - Oct 30, 2017
P1, N=30, Active, not recruiting, Sponsor: Genentech, Inc.
Active, not recruiting --> Completed N=100 --> 30 | Trial primary completion date: Dec 2017 --> Apr 2018
- ||| Avastin (bevacizumab) / Roche
Enrollment closed: BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer (clinicaltrials.gov) - Oct 30, 2017
P2, N=56, Active, not recruiting, Sponsor: AA Secord
N=100 --> 30 | Trial primary completion date: Dec 2017 --> Apr 2018 Recruiting --> Active, not recruiting
- | cisplatin / Generic mfg., paclitaxel / Generic mfg.
Trial primary completion date: Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and IIA2 Cervical Cancer Followed by Radical Hysterectomy (clinicaltrials.gov) - Oct 30, 2017
P2, N=64, Recruiting, Sponsor: Chang Gung Memorial Hospital
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2019 --> Dec 2023
- | Enrollment closed, Trial primary completion date: Advancing HIV Prevention and Linkage to Care Among MSM With Gamification (clinicaltrials.gov) - Oct 30, 2017
P=N/A, N=120, Active, not recruiting, Sponsor: University of California, Berkeley
Trial primary completion date: Dec 2019 --> Dec 2023 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Dec 2017
- | Enrollment change: Repeat Sexually Transmitted Infection (STI) Patients: Tailored Socio-Contextual Intervention to Reduce HIV Risk (clinicaltrials.gov) - Oct 27, 2017
P=N/A, N=130, Completed, Sponsor: University of Wisconsin, Milwaukee
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Dec 2017 N=500 --> 130
- || Enrollment change: Single Center, Prospective Controlled Pilot Study of the OvaPrime Procedure (clinicaltrials.gov) - Oct 27, 2017
P=N/A, N=95, Recruiting, Sponsor: OvaScience, Inc.
N=500 --> 130 N=50 --> 95
- | Enrollment closed, Trial initiation date, Trial primary completion date: Dietary Treatment of Endometriosis-related Irritable Bowel Syndrome (clinicaltrials.gov) - Oct 27, 2017
P=N/A, N=22, Active, not recruiting, Sponsor: University of Aarhus
N=50 --> 95 Not yet recruiting --> Active, not recruiting | Initiation date: Nov 2016 --> Jul 2017 | Trial primary completion date: May 2017 --> Dec 2017
- ||| ISA101 / ISA Pharma
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: CervISA: Study of the Therapeutic Vaccine (ISA101/ISA101b) to Treat Advanced or Recurrent Cervical Cancer (clinicaltrials.gov) - Oct 27, 2017
P1/2, N=100, Active, not recruiting, Sponsor: ISA Pharmaceuticals
Not yet recruiting --> Active, not recruiting | Initiation date: Nov 2016 --> Jul 2017 | Trial primary completion date: May 2017 --> Dec 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2017 --> Apr 2018
- | Trial completion, Phase classification, Enrollment change, Trial primary completion date: Surgical Success After Laparoscopic vs Abdominal Hysterectomy (clinicaltrials.gov) - Oct 26, 2017
P=N/A, N=100, Completed, Sponsor: University of Texas Southwestern Medical Center
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2017 --> Apr 2018 Recruiting --> Completed | Phase classification: P4 --> PN/A | N=75 --> 100 | Trial primary completion date: Jun 2016 --> Dec 2016
- | Trial completion, Enrollment change: VLSCBCPPTLIL: Vulvar Lichen Sclerosus: Comparison Between Clobetasol Propionate, Photodynamic Therapy and Low-Intensity Laser (clinicaltrials.gov) - Oct 26, 2017
P=N/A, N=30, Completed, Sponsor: Daniela de Fátima Teixeira da Silva
Recruiting --> Completed | Phase classification: P4 --> PN/A | N=75 --> 100 | Trial primary completion date: Jun 2016 --> Dec 2016 Active, not recruiting --> Completed | N=60 --> 30
- | Preclinical, Trial primary completion date: Antimullerian Hormone Versus Antral Follicle Count for Determination of Gonadotrophin Dosing in IVF (clinicaltrials.gov) - Oct 26, 2017
P=N/A, N=200, Recruiting, Sponsor: The University of Hong Kong
Active, not recruiting --> Completed | N=60 --> 30 Trial primary completion date: Apr 2017 --> Apr 2018
- | Trial primary completion date, HEOR: Sexual Functioning in Cervical Cancer Survivors (clinicaltrials.gov) - Oct 25, 2017
P=N/A, N=165, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Apr 2017 --> Apr 2018 Trial primary completion date: Dec 2018 --> Dec 2019
- | Trial primary completion date: DNA Array Analysis of Patients With Cervical Cancer (clinicaltrials.gov) - Oct 25, 2017
P=N/A, N=18, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2018 --> Dec 2019 Trial primary completion date: Dec 2018 --> Dec 2019
- | Trial primary completion date: What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography (clinicaltrials.gov) - Oct 25, 2017
P1, N=49, Active, not recruiting, Sponsor: University of Michigan
Trial primary completion date: Dec 2018 --> Dec 2019 Trial primary completion date: Nov 2018 --> May 2018
- | metformin / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women (clinicaltrials.gov) - Oct 25, 2017
P2, N=10, Completed, Sponsor: University of Arkansas
Trial primary completion date: Nov 2018 --> May 2018 Recruiting --> Completed | N=40 --> 10 | Trial primary completion date: Jun 2018 --> Aug 2016
- | progesterone / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Treatment of Infertility by Collagen Scaffold Loaded With Umbilical Cord Derived Mesenchyma Stem Cells (clinicaltrials.gov) - Oct 24, 2017
P=N/A, N=26, Completed, Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Recruiting --> Completed | N=40 --> 10 | Trial primary completion date: Jun 2018 --> Aug 2016 Active, not recruiting --> Completed | N=20 --> 26 | Trial primary completion date: Dec 2015 --> Jan 2015
- | Enrollment change, Trial withdrawal, Trial primary completion date: The Application of Probe-based Confocal Laser Endomicroscopy in the Diagnosis of Deep Endometriosis (clinicaltrials.gov) - Oct 24, 2017
P=N/A, N=0, Withdrawn, Sponsor: Dr. Ofir Harnoy MD
Active, not recruiting --> Completed | N=20 --> 26 | Trial primary completion date: Dec 2015 --> Jan 2015 N=10 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: May 2017 --> Oct 2017
- ||| HSV vaccine (GEN-003) / Genocea, Shionogi
Trial completion, Enrollment change, Trial primary completion date: Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity (clinicaltrials.gov) - Oct 20, 2017
P=N/A, N=140, Completed, Sponsor: Genocea Biosciences, Inc.
N=10 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: May 2017 --> Oct 2017 Active, not recruiting --> Completed | N=225 --> 140 | Trial primary completion date: Dec 2018 --> Jul 2017
- | merigolix (TU2670) / Tium Bio, Daewon Pharma
Trial completion, Trial primary completion date: Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of SKI2670 (clinicaltrials.gov) - Oct 20, 2017
P1, N=16, Completed, Sponsor: SK Chemicals Co.,Ltd.
Active, not recruiting --> Completed | N=225 --> 140 | Trial primary completion date: Dec 2018 --> Jul 2017 Recruiting --> Completed | Trial primary completion date: Feb 2017 --> Aug 2016
- | Ophena (ospemifene) / Shionogi
Trial primary completion date: Ospemifene vs. Conjugated Estrogens in the Treatment of Postmenopausal Sexual Dysfunction (clinicaltrials.gov) - Oct 19, 2017
P4, N=104, Recruiting, Sponsor: Emory University
Recruiting --> Completed | Trial primary completion date: Feb 2017 --> Aug 2016 Trial primary completion date: Aug 2017 --> Nov 2017
- Korlym (mifepristone) / Corcept Therap
Trial primary completion date, Combination therapy, Metastases: Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors (clinicaltrials.gov) - Oct 19, 2017
P1, N=37, Active, not recruiting, Sponsor: Corcept Therapeutics
Trial primary completion date: Aug 2017 --> Nov 2017 Trial primary completion date: Sep 2017 --> Dec 2017
- ||||||| Trial completion, Preclinical, Trial primary completion date: Phase III Study Comparing Efficacy and Safety of AFOLIA vs Gonal-f® RFF in Women (35 to 42) Undergoing IVF (clinicaltrials.gov) - Oct 18, 2017
P3, N=1100, Completed, Sponsor: Fertility Biotech AG
Trial primary completion date: Sep 2017 --> Dec 2017 Trial primary completion date: Jan 2017 --> Sep 2015 | Active, not recruiting --> Completed
- | cisplatin / Generic mfg.
Trial primary completion date, Metastases: Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer (clinicaltrials.gov) - Oct 18, 2017
P3, N=590, Recruiting, Sponsor: Korea Cancer Center Hospital
Trial primary completion date: Jan 2017 --> Sep 2015 | Active, not recruiting --> Completed Trial primary completion date: Mar 2017 --> Mar 2020
- | Trial completion, Enrollment change, Trial primary completion date: Lifestyle Intervention for Polycystic Ovary Syndrome: Pulse-Based Diet and Exercise (clinicaltrials.gov) - Oct 17, 2017
P=N/A, N=95, Completed, Sponsor: University of Saskatchewan
Trial primary completion date: Mar 2017 --> Mar 2020 Recruiting --> Completed | N=166 --> 95 | Trial primary completion date: Apr 2016 --> Jul 2017
- | veliparib (ABT-888) / AbbVie
Trial primary completion date, BRCA Biomarker, PARP Biomarker: Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy (clinicaltrials.gov) - Oct 16, 2017
P1, N=98, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed | N=166 --> 95 | Trial primary completion date: Apr 2016 --> Jul 2017 Trial primary completion date: Jun 2016 --> May 2011
- |||| Rekovelle (follitropin delta) / Ferring, Menopur (menotropin) / Ferring
Trial completion: MEGASET HR: MENOPUR (clinicaltrials.gov) - Oct 13, 2017
P4, N=620, Completed, Sponsor: Ferring Pharmaceuticals
Trial primary completion date: Jun 2016 --> May 2011 Active, not recruiting --> Completed
- | Enrollment closed, Trial primary completion date, BRCA Biomarker: Identification and Referral of Women at Risk for Hereditary Breast/Ovarian Cancer (clinicaltrials.gov) - Oct 12, 2017
P=N/A, N=665, Active, not recruiting, Sponsor: Emory University
Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Sep 2017 --> Dec 2017
- ||||||| carboplatin / Generic mfg., paclitaxel / Generic mfg., nintedanib / Generic mfg.
Trial completion, Combination therapy, Metastases: LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer (clinicaltrials.gov) - Oct 11, 2017
P3, N=1366, Completed, Sponsor: Boehringer Ingelheim
Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Sep 2017 --> Dec 2017 Active, not recruiting --> Completed
- | Cetrotide (cetrorelix) / EMD Serono
Trial completion, Preclinical, Enrollment change: GnRH Antagonist Versus GnRH Agonist in Polycystic Ovary Syndrome During in Vitro Fertilization - Embryo Transfer (clinicaltrials.gov) - Oct 10, 2017
P3, N=43, Completed, Sponsor: Seoul National University Hospital
Active, not recruiting --> Completed Recruiting --> Completed | N=267 --> 43